PRRG4 Inhibitors
Chemical inhibitors of PRRG4 function by impeding the activation or activity of various kinases that are responsible for the phosphorylation and subsequent regulation of the protein. Staurosporine acts as a broad-spectrum kinase inhibitor, targeting various kinases that would otherwise catalyze the phosphorylation of PRRG4, thus preventing its activation. Similarly, Bisindolylmaleimide I and Gö6976 specifically inhibit Protein Kinase C (PKC), which is known to modify a multitude of proteins including PRRG4. By inhibiting PKC, these chemicals directly decrease the phosphorylation level of PRRG4, affecting its functional state. LY294002 and Wortmannin both target phosphoinositide 3-kinases (PI3K), key enzymes in cellular signaling that can indirectly influence the phosphorylation status of PRRG4. By blocking PI3K activity, these inhibitors can reduce downstream signaling events that would lead to the modification of PRRG4.
Other inhibitors target specific pathways that could be involved in the regulation of PRRG4. SB203580 and PD98059 focus on the MAP kinase pathways; SB203580 inhibits p38 MAP kinase, while PD98059 and U0126 both inhibit MEK, an upstream kinase in the MAPK/ERK pathway. The inhibition of these kinases can lead to reduced phosphorylation of PRRG4 if it is a downstream target. Rapamycin, by inhibiting mTOR, a central regulator of cell growth and metabolism, affects the overall cellular context in which PRRG4 functions. PP2, by inhibiting Src family tyrosine kinases, and SP600125, by targeting c-Jun N-terminal kinase (JNK), can each lead to reduced phosphorylation and regulation of PRRG4 if its activity is associated with signaling pathways involving these kinases.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. PRRG4 is known to be phosphorylated by certain kinases, and staurosporine's broad kinase inhibition profile could result in the decreased phosphorylation of PRRG4, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I specifically inhibits Protein Kinase C (PKC). Since PKC can phosphorylate a wide range of substrates, including PRRG4, the inhibition of PKC by Bisindolylmaleimide I can decrease the phosphorylation and subsequent activity of PRRG4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Given that PI3K signaling can lead to downstream phosphorylation events, inhibiting PI3K with LY294002 could reduce the phosphorylation and activation of PRRG4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is involved in cellular responses to stress and cytokines. If PRRG4 is involved in p38 MAPK-regulated pathways, inhibition of p38 MAPK by SB203580 could lead to the functional inhibition of PRRG4. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MAP kinase kinase (MEK), which is upstream of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can reduce the activation of ERK and potentially inhibit the phosphorylation and function of PRRG4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and since mTOR is a central regulator of cell growth and metabolism, inhibiting it with rapamycin could inhibit processes that are essential for the functional activity of PRRG4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and like LY294002, it can prevent the phosphorylation of downstream proteins by inhibiting PI3K activity. Consequently, this could inhibit the activity of PRRG4. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If PRRG4 is regulated by JNK-mediated phosphorylation, inhibition of JNK by SP600125 could result in the functional inhibition of PRRG4. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. As Src kinases can phosphorylate multiple substrates including PRRG4, the inhibition by PP2 could prevent the activation and function of PRRG4. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. By inhibiting these kinases, U0126 could prevent the activation of ERK1/2, which could be responsible for phosphorylating PRRG4, thus inhibiting its function. | ||||||